SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls

Lupus. 2021 Dec;30(14):2318-2320. doi: 10.1177/09612033211063793. Epub 2021 Dec 7.

Authors

Hannah R Mathew¹, May Y Choi¹, Katherine Buhler¹, Xenia Gukova¹, Francesca S Cardwell², Heather Waldhauser¹, Ann E Clarke¹, Marvin J Fritzler¹

Affiliations

¹ Cumming School of Medicine, 2129University of Calgary, Calgary, AB, Canada.
² 8430University of Waterloo, Waterloo, ON, Canada.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Neutralizing / blood
Antibodies, Viral / blood
COVID-19* / epidemiology
Humans
Lupus Erythematosus, Systemic* / virology
SARS-CoV-2
Seroconversion
Seroepidemiologic Studies*

Substances

Antibodies, Neutralizing
Antibodies, Viral